Intravenous tigecycline as adjunctive or alternative therapy for severe refractory clostridium difficile infection

Clinical Infectious Diseases

Volumn 48, Issue 12, 2009, Pages 1732-1735

  Herpers, Bjorn L ^a,b   Vlaminckx, Bart ^a   Burkhardt, Olaf ^d   Blom, Harmjo ^b   Biemond Moeniralam, Hazra S ^a   Hornef, Mathias ^e   Welte, Tobias ^d   Kuijper, Edward J ^c  

^a Department of Medical Microbiology and Immunology ^*  (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c Department of Internal Medicine   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CEFUROXIME; CIPROFLOXACIN; GENTAMICIN; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN; VORICONAZOLE;

ADULT; AGED; ARTICLE; CASE REPORT; CATHETER INFECTION; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; NONHUMAN; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RELAPSE; SEPSIS; SEPTIC SHOCK; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ADULT; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; COMPLEMENTARY THERAPIES; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; TREATMENT OUTCOME;

EID: 66949167421     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/599224     Document Type: Article

References (12)

1. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile- associated enteric disease. Ann Intern Med 2006; 145:758-64.
2. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008;47:1162-70.
3. Kuijper EJ, Wilcox MH. Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection? Clin Infect Dis 2008;47:63-5.
4. Bartlett JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 2008;46:1489- 92.
5. Kapoor S. Treatment of Clostridium difficile disease in patients not responding to metronidazole. J Infect 2008; 56:394-5.
6. Baines SD, Saxton K, Freeman J, Wilcox MH. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2006;58:1062-5.
7. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51:2716-9.
8. Pepin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007; 102:2781-8.
9. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic van- comycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002; 35:690-6.
10. Doan TL, Fung HB, Mehta D, Riska PF. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther 2006;28:1079-106.
11. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986;27:1169-72.
12. Nord CE, Sillerstrom E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 2006; 50:3375-80.